Sunshine Lake Pharma Co., Ltd.
Quick facts
Marketed products
Phase 3 pipeline
- Ara-C±IDA · Oncology
Ara-C±IDA is a combination chemotherapy regimen that inhibits DNA synthesis and induces apoptosis in rapidly dividing cells. - Clifutinib · Other
- FLAG-IDA · Oncology
FLAG-IDA is a combination chemotherapy regimen that inhibits DNA synthesis and promotes apoptosis in rapidly dividing cells. - HEC585
HEC585 is an investigational therapeutic agent in phase 3 development by Sunshine Lake Pharma with an undisclosed mechanism of action. - Irinotecan/Tegafur · Oncology
Irinotecan inhibits topoisomerase I to prevent DNA unwinding during replication, while tegafur is a prodrug of fluorouracil that inhibits thymidylate synthase to disrupt nucleotide synthesis. - Lerotinib · Other
- LoDAC · Oncology
LoDAC is a low-dose cytarabine formulation designed to improve tolerability and efficacy in hematologic malignancies.
Phase 2 pipeline
Phase 1 pipeline
- [14C] Antaitavir Hasophate
- [14C]Clifutinib
- [14C]-HEC585
- [14C]-Larotinib
- [14C]- Rongliflozin
- [14C] Yiqibuvir
- Clifutinib with fasted state
- Clifutinib with fed state
- HEC 68498
- HEC110114
- HEC113995
- HEC113995 PA•H2O tablets
- HEC113995PA•H2O tablet
- HEC116094
- HEC122505MsOH
- HEC169096
- HEC169584 capsule
- HEC30654AcOH capsule
- HEC53856
- HEC68498
- HEC73077 tablets
- HEC74647
- HEC74647PA capsule
- HEC83518
- HEC83518 tablets
- HEC89736
- HEC93077
- HEC96719 tablets
- Insulin degludec injection, RD15003
- Insulin degludec, Tresiba
- Kangdaprevir Sodium Tablet
- Larotinib · Other
- Liraglutide injection,RD12014
- Litapiprant Tablet
- pyroglutamate rongliflozin capsules
- Yimitasvir Phosphate Capsule
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: